Wake Forest Bancshares, Inc. Announces First Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
16
Wake Forest Bancshares, Inc. Announces First Quarter Results

WAKE FOREST, N.C., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wake Forest Bancshares, Inc., (OTC BB: WAKE) parent company of Wake Forest Federal Savings and Loan Association, announced today that the Company reported earnings of $420,884 or $0.38 per share for its quarter ended December 31, 2018.  The Company reported earnings of $25,850 or $0.02 per share for the same quarter a year earlier.  The Company’s quarterly results last year were significantly impacted by the U.S. tax-overhaul legislation which caused the Company’s deferred tax assets to become less valuable.  Substantially all financial institutions have deferred tax assets which were required to be written down because such tax assets were established when corporate tax rates were at 35% and the tax legislation lowered that rate to 21%. The rate reduction triggered a one-time write down that amounted to $266,288 during the December 31, 2017 quarter.  Without regard to this adjustment, the Company’s results would have been $292,119 or $0.26 per share for the prior year’s first quarter.

In announcing the earnings, Renee H. Shaw, President and Chief Executive Officer, stated that the Company was pleased with the current quarter’s results, the highest quarterly results in over ten years.  The Company’s operations continue to be positively impacted by a lack of nonperforming loans as well as by rising interest rate margins created by greater loan demand and upward rate movements initiated by the Federal Reserve.  The Company was delighted to report that it continued to have no problem assets at any time during the current quarter.  In addition, the Company’s interest rate margin expanded to 3.65% during its current quarter from 3.27% reported for its fiscal year ended September 30, 2018 and 3.01% reported for the same quarter a year earlier.   

Economic conditions and residential home sales continue to show strength in our local markets.  Our real estate markets have benefited because we are a part of the Research Triangle area which is consistently recognized as one of the top regions in the country for economic activity and quality of life attributes.  During the current quarter, sales activity has remained strong, home prices have increased, and inventories of available homes have continued to remain tight.  In addition, our local area’s unemployment rate has continued to decline slightly and consistently remains one of the lowest in North Carolina.    

Although the Company had added growth in its loan portfolio during the current quarter, no additional loan loss provisions were necessary this quarter because of our sufficient level of loan loss allowances and lack of problem loans. The Company had no loan charge-offs in the current quarter and its loan loss allowance amounted to approximately 2.19% of total loans outstanding at December 31, 2018. 

Total assets of the Company amounted to $104,307,895 at December 31, 2018.  Total loans receivable and deposits outstanding at December 31, 2018 amounted to $64,804,087 and $77,969,904, respectively.  Wake Forest Bancshares Inc.’s tier 1 capital leverage ratio was 23.91% at December 31, 2018.

Wake Forest Bancshares, Inc. has 1,123,452 shares of common stock outstanding.  Based in Wake Forest, North Carolina since 1922, the Company conducts business as Wake Forest Federal from its office in Wake Forest, (Wake County), North Carolina.

Contact: Renee H. Shaw, CEO
(919) 556-5146

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

Exro Technologies Reveals Quarterly Progress and Financial Insights

Updated Category News Views 362

Exro Technologies Reports First Quarter Results Exro Technologies Inc. (TSX: EXRO), a prominent tech company specializing in power control solutions for electric vehicles and energy storage, has recently announced its financial results for the first quarter of the year. This highlights their ongoing transition from technology validation towards commercial operations and...

Continue Reading
dsm-firmenich Appoints New Leaders to Propel Future Growth

Updated Category News Views 548

dsm-firmenich Welcomes New Executive Committee Members dsm-firmenich is set to usher in a transformative era by strengthening its Executive Committee, as it embarks on a journey to intensify its consumer-centered approach. This restructuring aims to solidify its standing as a top-tier partner in creation and innovation across the nutrition, health, and beauty sectors. The...

Continue Reading
Insight Partners Rolls Out $12.5B for Software Innovation Growth

Updated Category News Views 805

Insight Partners Launches New Funds to Propel Software Innovation Global software investor, Insight Partners, has recently celebrated a significant milestone by announcing the closing of its thirteenth flagship fund alongside a dedicated buyout co-invest fund, collectively known as "Fund XIII". This announcement is particularly special as it coincides with the firm's 30th...

Continue Reading
Acumatica's AI Innovations Transform Business Operations

Updated Category News Views 123

Acumatica's AI Innovations Transform Business Operations During an inspiring keynote at a recent summit, Acumatica showcased its commitment to revolutionizing business operations with an AI-first product strategy. This innovative approach aims to significantly enhance how small and mid-sized businesses operate, addressing the real-world challenges they face. With advanced...

Continue Reading
Microbiological Testing of Water Market Growth Forecasts

Updated Category News Views 101

The Expanding Microbiological Testing of Water Market As the demand for clean and safe water continues to surge, the global microbiological testing of water market is set to experience significant growth, reaching an impressive $2.3 billion by 2027, with a robust compound annual growth rate (CAGR) of 7.4%. The rising consciousness among consumers regarding the importance...

Continue Reading